Daniel A. Pollyea, MD, MS (IMAGE) University of Colorado Anschutz Medical Campus Caption Daniel A. Pollyea, MD, MS and colleagues report clinical trial results leading to FDA approval of ivosidenib against IDH1+ AML. Credit University of Colorado Cancer Center Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.